11/5/2026

speaker
Operator
Conference Call Operator

Hello and welcome everyone joining today's Envoy Medical Q3 2026 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the conference over to Phil Carlson, KCSA Managing Director. Please go ahead.

speaker
Phil Carlson
Managing Director, KCSA

Thank you, Operator. Good morning and welcome, everyone, to the Envoy Medical Third Quarter 2026 Earnings Conference Call. This is a special moment as this is Envoy Medical's first ever quarterly earnings call. I'm joined today by members of Envoy Medical's leadership team, including Brent Lucas, Chief Executive Officer, and Robbie Potashnik, Chief Accounting Officer and VP of Finance. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. Comments made on this call that look forward in time involve risks and uncertainties in our forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including statements regarding Amboy Medical's clinical, regulatory, and commercial plans, Strategies and estimates, the timing, results, data, and outcomes of the clinical trial, timing of FDA submissions and potential approval, and expectations of financial or operational performance are based on management's current plans and assumptions, and actual results may differ materially. Please refer to the company's filings with the SEC, including our Form 10-Q for the quarter ended September 30, 2026, and our Form 10-K for the fiscal year ended December 31, 2025. for a detailed discussion on the risks and uncertainties facing Envoy Medical. With that, I'd now like to turn the call over to Envoy Medical's Chief Executive Officer, Brent Lucas. Brent, please go ahead.

speaker
Brent Lucas
Chief Executive Officer, Envoy Medical

Thank you, Phil, and good morning, everyone. Before we get into the quarter, we would like to take a few minutes to discuss who we are as a company. Many of you have supported us for years, but a growing number of investors around the world are new to Envoy Medical's story. Whether you are a long-term investor or just getting to know us, we hope you will leave today's call with an understanding of why we are so energized about Envoy Medical's future. We believe Envoy Medical is on the cusp of something transformative. With our investigational acclaimed fully implanted cochlear implant, we believe we are uniquely positioned to reshape the multi-billion dollar cochlear implant market. If our assumptions prove correct, Some may one day call Envoy Medical an overnight success. The reality is that our journey to this point spans more than three decades and over $350 million of invested capital. Rome, as they say, was not built in a day. Envoy Medical was founded in 1995 with a clear goal, to create a fully implanted device that works with the natural ear. The founding principles were simple. Avoid microphones and externally worn components at all costs. And use the body's natural hearing pathway to capture sound. The benefits of a fully implanted hearing device were compelling. Nothing to wear on or behind your ear. The ability to hear all day and all night. No expensive external hardware to lose or break. No discomfort or annoyance from wearing something on the side of your head all day. The potential for better sound localization, fewer limits on everyday activities, and of course, nothing for others to see. That was the dream an Envoy Medical set out to make it a reality. Our solution was a middle ear sensor that leverages the natural hearing pathway. No microphone on or behind the ear. No microphone buried under the skin. Instead, the sensor picks up vibrations of the middle ear and uses them as the signal. much as the natural ear does. We first validated our sensor technology in the Esteem fully implanted active middle ear implant. The Esteem fully implanted hearing device is the first and currently the only of its kind to receive FDA approval. Roughly 1,000 Esteem devices have been implanted, some more than two decades ago in early clinical trials. We believe no company has more experience with fully implanted hearing devices than Envoy Medical. Unfortunately for patients with hearing loss and the professionals who serve them, CMS classified the Esteem as a hearing aid. That classification made it ineligible for Medicare coverage and, in practice, limited patients' access to the technology. We continue to believe that fully implanted active middle ear implants are hearing prosthetics, not hearing aids, and should be covered by public and private payers. If that policy changes, we believe the Esteem would be well positioned to benefit. In 2015, we shifted our focus to an opportunity that had been calling for our attention for two decades, fully implanted, invisible cochlear implants. Cochlear implants have been commercially available in the United States since the 1980s and are well established as an effective solution for severe to profound hearing loss. Yet only a small fraction of adult candidates, roughly 5%, have pursued one. We believe the significant reason for this low penetration is that most people do not want to live with or be limited by an external component worn on the side of their head.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API